Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy

MeSH terms

• Adult
• Aminoglycosides / administration & dosage*
• Aminoglycosides / adverse effects
• Antibodies, Monoclonal / administration & dosage*
• Antibodies, Monoclonal / adverse effects
• Antibodies, Monoclonal, Humanized
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Chemotherapy, Adjuvant
• Cohort Studies
• Drug Recalls
• Drug Resistance, Neoplasm / drug effects
• Etoposide / administration & dosage*
• Etoposide / adverse effects
• Female
• Gemtuzumab
• Humans
• Leukemia, Myeloid, Acute / diagnosis
• Leukemia, Myeloid, Acute / drug therapy*
• Male
• Middle Aged
• Mitoxantrone / administration & dosage*
• Mitoxantrone / adverse effects
• Remission Induction
• Withholding Treatment